Our collective results of GEP, MYC mutations, and Blimp-1 expression (indicating commitment to plasma cell differentiation) [52-54] in CD5+ and CD5− DLBCL (Tables 2, 4) suggest that subsets of CD5+ DLBCL may originate from pre-GC, memory B-cells, or neoplasms differentiated into plasma cells yet never through GC reaction [60, 61]. The gene discussed is PRDM1; the disease is neoplasm.